96% of Patients Experience NO Recurrence of Brain Cancer After IsoRay Treatment
IsoRay, Inc. (ISR – $1.76), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of cancers of the prostate, brain, lung, head and neck and gynecological, announced exceptional results conducted by researchers at the Barrow Neurological Institute, one of the world’s foremost brain cancer research and treatment sites. The Barrow study reported on […]
Read more